Patient-reported Perceptions of Brexanolone in the Treatment of Postpartum Depression: A Qualitative Analysis

Overview

Journal Ment Health Clin

Specialty Psychiatry

Date 2023 Jan 16

PMID 36644587

Authors

Aaron Salwan

Megan Maroney

Lisa Tremayne

Affiliations

Soon will be listed here.

Abstract

Introduction: Brexanolone demonstrates short-term efficacy for the treatment of postpartum depression (PPD). Postpartum depression is linked to infanticide and maternal suicide, and current treatment often fails to adequately control depressive symptoms. The purpose of this analysis is to further understand the experience(s) of women who have received brexanolone for the treatment of PPD.

Methods: Semistructured interviews modeled after the theory of planned behavior (TPB) were conducted to assess women's perceptions of treatment for PPD with brexanolone. Women who received treatment with brexanolone at this inpatient facility were eligible to participate in this study. The TPB is often used to predict intention to perform health-related behaviors. Semistructured interviews were recorded and transcribed, and thematic analysis was conducted to identify common ideas across all interviews. Follow-up assessment of depressive and anxious symptoms was also conducted using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Results: Five of the 10 women who received treatment with brexanolone at this facility were interviewed, and common themes related to the TPB were analyzed. Attitudes toward brexanolone were favorable, and having a strong support system was a motivating factor in receiving treatment for PPD. Insurance approval, need for childcare, and poor understanding of symptoms of PPD were barriers to receiving treatment with brexanolone. Symptoms of depression and anxiety were rated as low at the time of the follow-up interview as measured by the PHQ-9 (mean 1.6, range 1 to 3) and GAD-7 (mean 2.8, range 2 to 4), respectively.

Discussion: Brexanolone rapidly and sustainably reduced symptoms of PPD and was well-received by patients. Despite significant barriers to use, women who received treatment with brexanolone advocated for its availability as well as increased awareness of PPD.

Citing Articles

The lived experience of postpartum depression and psychosis in women: a bottom-up review co-written by experts by experience and academics.

Fusar-Poli P, Estrade A, Mathi K, Mabia C, Yanayirah N, Floris V World Psychiatry. 2025; 24(1):32-45.

PMID: 39810658 PMC: 11733465. DOI: 10.1002/wps.21264.

Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression.

Patil A, Koul S Curr Pharm Des. 2024; 30(33):2587-2596.

PMID: 39075953 DOI: 10.2174/0113816128309913240704095334.

Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.

Marecki R, Kaluska J, Kolanek A, Hakalo D, Waszkiewicz N Front Psychiatry. 2023; 14:1298359.

PMID: 38116383 PMC: 10729607. DOI: 10.3389/fpsyt.2023.1298359.

References

Slomian J, Honvo G, Emonts P, Reginster J, Bruyere O . Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. Womens Health (Lond). 2019; 15:1745506519844044. PMC: 6492376. DOI: 10.1177/1745506519844044. View

Hellgren C, Akerud H, Skalkidou A, Backstrom T, Sundstrom-Poromaa I . Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology. 2014; 69(3):147-53. DOI: 10.1159/000358838. View

Bennett H, Einarson A, Taddio A, Koren G, Einarson T . Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004; 103(4):698-709. DOI: 10.1097/01.AOG.0000116689.75396.5f. View

Ismail T, Muda W, Bakar M . The extended Theory of Planned Behavior in explaining exclusive breastfeeding intention and behavior among women in Kelantan, Malaysia. Nutr Res Pract. 2016; 10(1):49-55. PMC: 4742311. DOI: 10.4162/nrp.2016.10.1.49. View

Hales D, Evenson K, Wen F, Wilcox S . Postpartum physical activity: measuring theory of planned behavior constructs. Am J Health Behav. 2010; 34(4):387-401. PMC: 3327138. DOI: 10.5993/ajhb.34.4.1. View

. ACOG Committee Opinion No. 757: Screening for Perinatal Depression. Obstet Gynecol. 2019; 132(5):e208-e212. DOI: 10.1097/AOG.0000000000002927. View

Kingston D, Tough S . Prenatal and postnatal maternal mental health and school-age child development: a systematic review. Matern Child Health J. 2013; 18(7):1728-41. DOI: 10.1007/s10995-013-1418-3. View

Paris R, Bolton R, Weinberg M . Postpartum depression, suicidality, and mother-infant interactions. Arch Womens Ment Health. 2009; 12(5):309-21. DOI: 10.1007/s00737-009-0105-2. View

Downe S, Finlayson K, Tuncalp O, Gulmezoglu A . Provision and uptake of routine antenatal services: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2019; 6:CD012392. PMC: 6564082. DOI: 10.1002/14651858.CD012392.pub2. View

10.

Mauri M, Oppo A, Borri C, Banti S . SUICIDALITY in the perinatal period: comparison of two self-report instruments. Results from PND-ReScU. Arch Womens Ment Health. 2012; 15(1):39-47. DOI: 10.1007/s00737-011-0246-y. View

11.

Hansotte E, Payne S, Babich S . Positive postpartum depression screening practices and subsequent mental health treatment for low-income women in Western countries: a systematic literature review. Public Health Rev. 2018; 38:3. PMC: 5809911. DOI: 10.1186/s40985-017-0050-y. View

12.

Bauman B, Ko J, Cox S, DAngelo Mph D, Warner L, Folger S . Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020; 69(19):575-581. PMC: 7238954. DOI: 10.15585/mmwr.mm6919a2. View

13.

Do T, Hu Z, Otto J, Rohrbeck P . Depression and suicidality during the postpartum period after first time deliveries, active component service women and dependent spouses, U.S. Armed Forces, 2007-2012. MSMR. 2013; 20(9):2-7. View

14.

Josefsson A, Sydsjo G . A follow-up study of postpartum depressed women: recurrent maternal depressive symptoms and child behavior after four years. Arch Womens Ment Health. 2007; 10(4):141-5. DOI: 10.1007/s00737-007-0185-9. View

15.

Stewart D, Vigod S . Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annu Rev Med. 2019; 70:183-196. DOI: 10.1146/annurev-med-041217-011106. View

16.

Cai D, Zheng W, Sim K, Ungvari G, Peng X, Ning Y . Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res. 2019; 279:83-89. DOI: 10.1016/j.psychres.2019.07.006. View

17.

Dugdale S, Elison S, Davies G, Ward J . Applying Behavior Change Theories and Qualitative Methods in Substance Misuse Implementation Research: Conceptualizing the Adoption of Breaking Free Online in Real-World Clinical Practice. Qual Health Res. 2017; 27(7):1049-1059. DOI: 10.1177/1049732316683379. View

18.

Goodman J, Tyer-Viola L . Detection, treatment, and referral of perinatal depression and anxiety by obstetrical providers. J Womens Health (Larchmt). 2010; 19(3):477-90. DOI: 10.1089/jwh.2008.1352. View

19.

Maguire J, Mody I . GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008; 59(2):207-13. PMC: 2875248. DOI: 10.1016/j.neuron.2008.06.019. View

20.

Wisner K, Sit D, McShea M, Rizzo D, Zoretich R, Hughes C . Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013; 70(5):490-8. PMC: 4440326. DOI: 10.1001/jamapsychiatry.2013.87. View